Market Overview

AtriCure Announces Completion of Patient Enrollment in the CONVERGE IDE Clinical Trial


Landmark study is the first prospective, randomized study comparing
the Convergent approach to endocardial catheter ablation in persistent
and long-standing persistent atrial fibrillation patients

AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical
treatments for atrial fibrillation (Afib) and left atrial appendage
management, today announced it has completed enrollment of the full
cohort of 153 patients in the CONVERGE IDE clinical trial.

The CONVERGE IDE trial is a landmark prospective, randomized trial
underway in the United States comparing the Convergent approach to
endocardial catheter ablation for patients with persistent or
long-standing persistent Afib. The Convergent approach is a
multi-disciplinary therapy in which a closed-chest epicardial ablation
is performed by a surgeon, and then complemented by an endocardial
catheter ablation performed by an electrophysiologist. Patients were
enrolled at 25 sites across the United States, along with 2 sites in the
United Kingdom.

"The full enrollment of the CONVERGE clinical trial is a significant
milestone for AtriCure," said Mike Carrel, President and Chief Executive
Officer. "This study is the first of its kind, evaluating the
multi-disciplinary Convergent approach against catheter ablation for
patients who suffer from the most serious forms of Afib. We believe that
once concluded, this study will be a meaningful step forward in
demonstrating the safety and effectiveness of the Convergent approach."

The CONVERGE study's primary efficacy endpoint is for enrolled patients
to be Afib, atrial tachycardia, and atrial flutter free, absent class I
and III AADs except for a previously failed or intolerant class I or III
anti-arrhythmic drugs, with no increase in dosage following the 3-month
blanking period through the 12 months' post procedure follow-up visit.
The last patient follow-up is expected to be sometime in the third
quarter of 2019, after which the company will submit final documentation
to the Food and Drug Administration and seek a pre-market approval (PMA).

"The CONVERGE trial is an important step forward for the cardiology
community in furthering available treatment options for Afib patients,"
said Dr. David De Lurgio, principal investigator (PI) for the trial, and
Director of Electrophysiology at Emory Heart and Vascular Center in
Atlanta, GA. "This study is differentiated from other studies currently
being conducted on the persistent and long-standing persistent
population, because there is no time restriction on the duration of
diagnosed Afib in the patients being studied. Patients with persistent
and long-standing persistent Afib make up a very large percentage of the
diagnosed population, and the trial is intended to study the safety and
effectiveness of the Convergent approach for those patients that have
limited other options for effective treatment."

More information regarding the trial, including inclusion and exclusion
criteria and primary and secondary outcome measures, can be found here:

About AtriCure, Inc.

AtriCure, Inc. provides innovative technologies for the treatment of
Afib and related conditions. Afib affects more than 33 million people
worldwide. Electrophysiologists and cardiothoracic surgeons around the
globe use AtriCure technologies for the treatment of Afib and reduction
of Afib related complications. AtriCure's Isolator® Synergy™ Ablation
System is the first and only medical device to receive FDA approval for
the treatment of persistent Afib. AtriCure's AtriClip Left Atrial
Appendage (LAA) Exclusion System products are the most widely sold LAA
management devices worldwide, with more than 150,000 implanted to date.
For more information, visit or follow us on Twitter

Forward-Looking Statements

This press release contains "forward-looking statements"– that is,
statements related to future events that by their nature address matters
that are uncertain. For details on the uncertainties that may cause our
actual results to be materially different than those expressed in our
forward-looking statements, visit
as well as our Annual Reports on Form 10-K and Quarterly Reports on Form
10-Q which contain risk factors. We do not undertake to update our
forward-looking statements. This document also includes forward-looking
projected financial information that is based on current estimates and
forecasts. Actual results could differ materially.

View Comments and Join the Discussion!